Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.73 |
| ▸ | BCR | P11274 | 2/20 | 0.73 |
| ▸ | BRAF | P15056 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 15/20 | 0.67 |
| ▸ | KDR | P35968 | 9/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.65 |
| ▸ | EGFR | P00533 | 8/20 | 0.65 |
| ▸ | HCK | P08631 | 8/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.65 |
| ▸ | MTOR | P42345 | 8/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.65 |
| ▸ | PRKDC | P78527 | 8/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.65 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.62 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.62 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.62 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12123497 | 0.92 | ABL1 (0.69) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL12123667 | 0.91 | SRC (0.69) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL12120509 | 0.88 | SRC (0.70) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL1318875 | 0.84 | RET (0.77) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL29496472 | 0.84 | RET (0.77) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL12123455 | 0.84 | ABL1 (0.70) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL14985435 | 0.82 | RET (0.73) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL18288576 | 0.81 | RET (0.65) | ABL1BCRBRAFSRCKDR | |
| SCHEMBL14982737 | 0.80 | SRC (0.84) | ABL1SRCKDRPIK3CDEGFR | |
| SCHEMBL17936047 | 0.80 | SRC (1.00) | ABL1BCRBRAFSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2010045542-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | ABL1 46/4885BCR 192/4885BRAF 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.